Loading...

APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) Antibody

Pricing & Availability
Clone
RB6-8C5 (See other available formats)
Regulatory Status
RUO
Other Names
Gr-1
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
RB6-8C5_APCCyanine7_Ly6G-Ly6C_Antibody_020119
C57BL/6 mouse bone marrow stained with CD11b FITC and Ly-6G/Ly-6C (Gr-1) (clone RB6-8C5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right). Dot plots are gated on myeloid cell population).
  • RB6-8C5_APCCyanine7_Ly6G-Ly6C_Antibody_020119
    C57BL/6 mouse bone marrow stained with CD11b FITC and Ly-6G/Ly-6C (Gr-1) (clone RB6-8C5) APC/Cyanine7 (left) or Rat IgG2b, κ APC/Cyanine7 isotype control (right). Dot plots are gated on myeloid cell population).
Compare all formats See APC/Cyanine7 spectral data
Cat # Size Price Save
108423 25 µg ¥17,980
108424 100 µg ¥41,300
Description

Gr-1 is a 21-25 kD protein also known as Ly-6G/Ly-6C. This myeloid differentiation antigen is a glycosylphosphatidylinositol (GPI)-linked protein expressed on granulocytes and macrophages. In bone marrow, the expression levels of Gr-1 directly correlate with granulocyte differentiation and maturation; Gr-1 is also transiently expressed on bone marrow cells in the monocyte lineage. Immature Myeloid Gr-1+ cells play a role in the development of antitumor immunity.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Raised against granulocytes of mouse origin
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is = 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C19. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A819. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.420.

The RB6-8C5 antibody has been used to identify peripheral blood neutrophils and deplete granulocytes in vivo. Additional reported applications (for relevant formats of this clone) include: in vitro complement-mediated cytotoxicity2, in vivo depletion3-5,9, immunoprecipitation1, immunohistochemical staining6 (including paraffin-embedded sections9,16,33-35, acetone-fixed frozen sections11 and zinc-fixed sections15), and Western blotting7. RB6-8C5 is not suitable for depletion of hepatic myeloid derived suppressor cells (MDSCs)20.

Special Note: For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 108436).

Application References

(PubMed link indicates BioLegend citation)
  1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (IP)
  2. Brummer E, et al. 1984. J. Leukocyte Biol. 36:505. (CMCD)
  3. Stoppacciaro A, et al. 1993. J. Exp. Med. 178:151. (Deplete)
  4. Tumpey TM, et al. 1996. J. Virol. 70:898. (Deplete)
  5. Czuprynski CJ, et al. 1994. J. Immunol. 152:1836. (Deplete)
  6. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  7. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819. (WB)
  8. Engwerda CR, et al. 2004. Am. J. Pathol. 165:2123.
  9. Brown CR, et al. 2004. Infect. Immun. 72:4956. (Deplete, IHC)
  10. Andoniou CE, et al. 2005. Nature Immunology 6:1011. (FC) PubMed
  11. Li M, et al. 2006. P. Natl. Acad. Sci USA 103:11736. (IHC)
  12. Dzhagalov I, et al. 2007. Blood 109:1620. (FC) PubMed
  13. Fazilleau N, et al. 2007. Nature Immunol. 8:753. (FC) PubMed
  14. Heuser M, et al. 2007. Blood 110:1639. (FC) PubMed
  15. Wang T, et al. 2007. Infect. Immun. 75:1144. (IHC)
  16. Bosio CM, et al. 2007. J. Immunol. 178:4538. (IHC)
  17. Boehme SA, et al. 2009. Int. Immunol. 21:81. (IHC)
  18. Piao Y, et al. 2012. Neuro Oncol. 14:1379. PubMed
  19. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
  20. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
  21. Li J, et al. 2012. Arthritis Rheum. 64:1098. PubMed
  22. Fan Q, et al. 2014. Cancer Res. 74:471. PubMed
  23. Korrer MJ, et al. 2014. PLoS One. 9:91370. PubMed
  24. Morshed M, et al. 2014. J Immunol. 192:5314. PubMed
  25. Collins C, et al. 2014. PNAS. 111:9899. PubMed
  26. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  27. Bianchi G, et al. 2014. Cell Death Dis. 5:1135. PubMed
  28. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  29. Roderick JE, et al. 2014. PNAS. 111:14436. PubMed
  30. Distel E, et al. 2014. Circ Res. 115:759. PubMed
  31. Iwai H, et al. 2015. Tuberculosis. 95:246. PubMed
  32. Charmsaz S, et al. 2015. PLoS One. 10:130692. PubMed
  33. Whiteland J, et al. 1994 J Histochem Cytochem 43:3 (IHC-P)
  34. Brown C, et al. 2003 J Immunology 171:2 (IHC-P)
  35. Obregon-Henao A, et al. PLoS One 8:11 (IHC-P)
Product Citations
  1. Hatzi K, et al. 2019. Nat Immunol. 20:86. PubMed
  2. Jaitin DA, et al. 2020. Cell. 178(3):686-698.e14.. PubMed
  3. Chung Y, et al. 2014. J Vis Exp. 89: 51660. PubMed
  4. Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed
  5. Bregolat NF, et al. 2022. Haematologica. 107:2454. PubMed
  6. Ramdas B, et al. 2022. Mol Ther. 30:2505. PubMed
  7. Sheng YH, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:789. PubMed
  8. Solier S, et al. 2023. Int J Mol Sci. 24:. PubMed
  9. Yazicioglu YF, et al. 2023. Nat Immunol. 24:991. PubMed
  10. Zhang H, et al. 2023. Pharmaceutics. 15:. PubMed
  11. Viny AD, et al. 2019. Cell Stem Cell. 25:682. PubMed
  12. Coleby R, et al. 2021. Clin Exp Rheumatol. :39. PubMed
  13. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  14. Leimkühler NB, et al. 2020. Cell Stem Cell. 28:637. PubMed
  15. Qiu F, et al. 2022. J Cancer. 13:2893. PubMed
  16. Liu J, et al. 2012. PLoS One. 7:e44044. PubMed
  17. Bhattacherjee A, et al. 2019. Commun Biol. 2:450. PubMed
  18. Pan W et al. 2017. Immunity. 47(2):284-297 . PubMed
  19. Mayers S, et al. 2019. BMC Biotechnol. 19:21. PubMed
  20. Kunimoto H, et al. 2018. Cancer Cell. 33:44. PubMed
  21. Gabbita S, et al. 2015. PLoS One. 10: e0137305. PubMed
  22. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  23. Chen X et al. 2017. Cell stem cell. 21(6):747-760 . PubMed
  24. Kleppe M et al. 2018. Cancer cell. 33(1):29-43 . PubMed
  25. Lehmann M, et al. 2016. J Leukoc Biol. 99: 1057 - 1064. PubMed
  26. Panea C, et al. 2021. Commun Biol. 4:913. PubMed
  27. Zhang C, et al. 2020. Cell Rep. 32:108206. PubMed
  28. Vettorazzi S, et al. 2015. Nat Commun. 6: 7796. PubMed
  29. Xiang W, et al. 2018. Nat Commun. 9:2574. PubMed
  30. Liu Z, et al. 2021. Immunity. 54(2):247-258.e7. PubMed
  31. Yang S, et al. 2022. J Exp Med. 219:. PubMed
  32. Firas J, et al. 2014. Differentiation. 87:193. PubMed
  33. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
  34. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  35. Yahagi A, et al. 2019. RMD Open. 5:e000853. PubMed
  36. Gagnon JD, et al. 2019. Cell Rep. 28:2169. PubMed
  37. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  38. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  39. Matthew B Buechler et al. 2019. Immunity. 51(1):119-130 . PubMed
  40. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  41. Zhang CR, et al. 2022. Blood Cancer Discov. 3:220. PubMed
  42. Xu G, et al. 2022. Front Pharmacol. 13:896601. PubMed
  43. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  44. Gerdes P, et al. 2022. Nat Commun. 13:7470. PubMed
  45. van den Berk P, et al. 2020. Cell Rep. 33:108533. PubMed
  46. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  47. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  48. Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed
  49. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
  50. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  51. Kong IY, et al. 2020. Cell Rep. 33:108290. PubMed
  52. Deets KA, et al. 2021. Elife. 10:. PubMed
  53. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  54. Young K, et al. 2021. Cell Stem Cell. . PubMed
  55. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  56. Ershaid N, et al. 2019. Nat Commun. 10:4375. PubMed
RRID
AB_2137485 (BioLegend Cat. No. 108423)
AB_2137485 (BioLegend Cat. No. 108424)

Antigen Details

Structure
21-25 kD
Distribution

Granulocytes, monocytes

Cell Type
Granulocytes, Monocytes, Neutrophils
Biology Area
Immunology, Innate Immunity
Antigen References

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399.
2. Jutila MA, et al. 1988. Eur. J. Immunol. 18:1819.
3. Goni O, et al. 2002. Int. Immunol. 14:1125.

Gene ID
17067 View all products for this Gene ID 546644 View all products for this Gene ID
UniProt
View information about Ly-6G Ly-6C on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All Ly-6G/Ly-6C Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Biotin anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
FITC anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PE/Cyanine5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC,IP,WB
PE/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 488 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IHC
Alexa Fluor® 647 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,SB
Alexa Fluor® 700 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 711™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Cyanine7 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Pacific Blue™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP/Cyanine5.5 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
PerCP anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 421™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 570™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Ultra-LEAF™ Purified anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC,IP,CMCD,Depletion,IHC,WB
Brilliant Violet 510™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 605™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Brilliant Violet 650™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Alexa Fluor® 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 IHC-F,FC
Purified anti-mouse Ly-6G/Ly-6C (Gr-1) (Maxpar® Ready) RB6-8C5 FC,CyTOF®
PE/Dazzle™ 594 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 750 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
TotalSeq™-A0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-C0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
TotalSeq™-B0116 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 PG
Spark Blue™ 550 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
APC/Fire™ 810 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Violet™ 423 anti-mouse Ly-6G/Ly-6C (GR-1) Antibody RB6-8C5 FC
Spark UV™ 387 anti-mouse Ly-6G/Ly-6C (GR-1) RB6-8C5 FC
Spark Violet™ 538 anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark PLUS UV395™ anti-mouse Ly-6G/Ly-6C (Gr-1) RB6-8C5 FC
Spark Red™ 718 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Spark Blue™ 574 anti-mouse Ly-6G/Ly-6C (Gr-1) (Flexi-Fluor™) RB6-8C5 FC
Go To Top Version: 3    Revision Date: 02/01/2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account